Navigation Links
Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting

basis for PPL-100's favorable resistance profile with Merck & Co., Inc. and Dr. Mark Wainberg from McGill University, which was presented by Merck at the XVI International HIV Drug Resistance Workshop. Ambrilia continues to follow-up with Merck in their advancement of the compound towards development in HIV/AIDS patients.

- On April 24th, Ambrilia announced the positive findings of a U.S. Phase I/II study which showed that its therapeutic peptide drug PCK3145 had clinical activity in late-stage prostate cancer patients. PCK3145 was found to be safe and well tolerated, and was shown to increase PSA (Prostate Specific Antigen) doubling time and down-regulate MMP-9 (a matrix metalloproteinase enzyme involved in facilitating tumor metastasis). Disease stabilization as assessed by time to radiographic progression was also observed in several patients. Ambrilia is currently evaluating various partnering and product development strategies to move forward with PCK3145.

- The pivotal Phase III clinical trial in Europe with Octreotide in acromegaly patients was initiated in February and Ambrilia obtained an IND with its U.S. licensing partner, Mallinckrodt, to conduct a pivotal Phase III clinical trial with Octreotide. Ambrilia expects to complete the Phase III clinical efficacy study towards the end of 2007, and the safety studies around mid 2008. Filing for approval by its licensing partners is expected during the course of 2008, starting with Europe and followed by North America.

CORPORATE

- On June 14, Ambrilia shareholders elected Mr. Richard La Rue, Vice-President, Legal Affairs and Human Resources of Ambrilia as a member of the Board.

- On June 13, the Board of Directors of Ambrilia appointed Frederic Porte, a director of the Company since January 2007, as its Chairman. Mr. Stephen G. Sudovar stepped down as a member of the Board and as its Executive Chairman, as well as interim Chief Executive Officer of the Company, for persona
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
6. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
7. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
8. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
9. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
Post Your Comments:
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... Jersey's State-designated entity on behalf of the New Jersey Department of Health, has ... Health Information Technology, an agency of the U.S. Department of Health and Human ...
(Date:7/30/2015)... ... July 30, 2015 , ... 1Heart Caregiver Services LLC is offering its ... Make Money in the Booming Homecare Business.” This will be held in its main ... , The event will be hosted by 1Heart’s very own Randy Clarito (Director of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... Santa Rosa, CA (PRWEB) , ... July 30, 2015 , ... At the presentation of ... topic of discussion was focused on research presented by the Journal of Arthroplasty ... normal tasks – like driving. , Results of the study confirm what Santa ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... for women to ensure their children have the nutrition required to grow into ... by offering discount cards for many prescription pre-natal vitamins. , Folic Acid , ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4
... Innovative technology such as electronic wristbands is developed to ... Human errors. Wristbands are developed which provides information about ... used in hospitals now to prescribe, dispense and administer ... bands contain electronic system which is similar to the ...
... the clinical trials involving lung cancer patients and it ... a frontline therapy for those with lung cancer. One ... regime in the elderly patients is the tolerability and ... tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity ...
... of Fair Trading is responsible for checking the profits ... to the NHS. They have to monitor that only ... should be reasonable. ,The Pharmaceutical Price Regulation ... legislates the agreement of the pricing and quality of ...
... out of deprivation from being in poverty and poor ... for heart disease is potentially denying// life saving preventive ... published ahead of print in the journal Heart. ... being allocated "primary preventive" treatment, is currently calculated using ...
... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
... called villi which increase the surface area of the intestine ... are covered in epithelial cells // which are constantly renewed ... top of the villi every day. ,Scientists found ... the bowel which, in healthy tissue, are immediately filled with ...
Cached Medicine News:Health News:Tarceva Found To Benefit Older Lung Cancer Patients 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Deprivation Can Cause Undetected Heart Problems 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2